We can’t show the full text here under this license. Use the link below to read it at the source.
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Using Glucagon-Like Peptide-1 Drugs to Restore Gut Balance for Obesity and Metabolic Health
AI simplified
Abstract
Obesity significantly impacts gut microbial composition, exacerbating metabolic dysfunction and weight gain.
- Glucagon-like peptide-1 (GLP-1) agonists may promote beneficial bacterial populations while reducing harmful species.
- These agents could enhance gut barrier integrity, potentially reducing permeability and systemic inflammation.
- GLP-1 agonists may improve metabolic functions by increasing the production of short-chain fatty acids, which serve as energy sources for colon cells.
- By increasing microbial diversity, GLP-1 agonists may help create a more resilient gut microbiome.
- Shifting gut microbiota toward a healthier profile is associated with disrupting the cycle of obesity-induced gut dysbiosis and inflammation.
AI simplified